Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

COCP vs AIM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

COCP Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 6–3 Matrix Metrics)

COCP Overall Winner 6-Pillar Tally: COCP 3 – 1 AIM (2 Tie) Matrix Metrics: COCP 6 – 3 AIM

As of Nov 16, 2026, Cocrystal Pharma, Inc. (COCP) is the stronger overall head-to-head candidate over AIM ImmunoTech Inc. (AIM) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). COCP carries a Unified Composite Score of 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin), whereas AIM carries 52.8/100 (HOLD) at $0.13 (2.0x Forward P/E, -11724.2% operating margin).

  • Composite vs. Pillar Nuance: While AIM currently prints a higher short-term Unified Composite Score (52.8/100 HOLD vs. COCP 47.1/100 HOLD), COCP captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-3063.6% vs. -11724.2% operating margin) and revenue trajectory (+26.9% vs. +4.0% YoY).
  • Technical & Structure Timing Caution: COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3); meanwhile AIM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About COCP vs AIM
COCP NASDAQ Head-to-Head Winner
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap $19.6M
TTM Revenue $330,000
Forward P/E N/M
Beta / 30D Vol 1.04β · 54% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 51.0 Fund 48.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $1.00 · SMA50: $1.08
AIM NYSE American
AIM ImmunoTech Inc.
Biological Products, (No Disgnostic Substances)
$0.13
-7.1% 1D
Market Cap $5.9M
TTM Revenue $95,000
Forward P/E 2.0x
Beta / 30D Vol 0.32β · 69% Vol
Unified Composite Score
52.8 / 100 HOLD
Tech 54.0 Fund 57.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.6%), weak momentum, RSI 32
RSI-14: 31.8 · SMA20: $0.16 · SMA50: $0.18

6-Pillar Scorecard Institutional Category Breakdown (COCP 3 – 1 AIM)

Columns: Metric · COCP · AIM
1. Valuation Multiples AIM
Forward P/E N/M 2.0x
Trailing P/E N/M 2.0x
PEG Ratio N/M 0.71x
EV / Revenue 49.7x 62.4x
2. Growth & Scale COCP
Revenue Growth (YoY) +26.9% +4.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $330,000 $95,000
Market Cap $19.6M $5.9M
3. Profitability & Quality COCP
Gross Margin N/A -23.2%
Operating Margin -3063.6% -11724.2%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -311.7% -2382.3%
4. Balance Sheet & Cash Flow COCP
Cash Generation (TTM) -$7.6M -$11M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.3M Net Cash $0.27 Book/Sh · -2382.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: COCP (6) vs AIM (3)
Institutional Metric COCP AIM Criterion Row Edge
Market Capitalization
Scale
$19.6M $5.9M Larger Scale COCP
Trailing P/E Ratio
Valuation
N/M 2.0x Lower Multiple AIM
Forward P/E Ratio
Valuation
N/M 2.0x Lower Multiple AIM
Revenue Growth (YoY)
Growth
+26.9% +4.0% Higher Growth COCP
Operating Margin (TTM)
Profitability
-3063.6% -11724.2% Higher Margin COCP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-311.7% -2382.3% Higher ROE COCP
52-Week Range Position
Momentum
19% ($1–$2) 1% ($0–$2) Stronger Trend COCP
Beta / 30D Volatility
Risk Regime
1.04β · 54% Vol 0.32β · 69% Vol Lower Realized Risk COCP
Unified Institutional Score
Composite Signal
47.1 / 100 (HOLD) 52.8 / 100 (HOLD) Higher Composite AIM
Trailing 12M Revenue (USD)
Operating Scale
$330,000 $95,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -23.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 49.7x EV/Rev 0.71x PEG · 62.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.6M ($3.3M Net Cash) -$11M EBITDA ($0.27 Book/Sh · -2382.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon COCP +18.63 pp
COCP: -2.01% · AIM: -20.64%
3M Horizon COCP +35.52 pp
COCP: -7.45% · AIM: -42.97%
6M Horizon COCP +52.0 pp
COCP: -15.3% · AIM: -67.3%
1Y Horizon COCP +87.93 pp
COCP: -2.96% · AIM: -90.89%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period COCP Revenue AIM Revenue COCP Op. Margin AIM Op. Margin Margin Leader
FY2018 N/A $0M N/A -3132.4% AIM
FY2019 $10M $0M -737.4% -8887.9% COCP
FY2020 $0M $0M -476.0% -9295.7% COCP
FY2021 N/A $0M N/A -13954.1% AIM
FY2022 N/A $0M N/A -14129.8% AIM
FY2023 N/A $0M N/A -15800.0% AIM
FY2024 N/A $0M N/A -11630.6% AIM
FY2025 N/A $0M N/A -13254.5% AIM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AIM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AIM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $19.6M market capitalization and -3063.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AIM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.9M market capitalization and -11724.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ COCP vs AIM Key Questions & Quantitative Answers

As of Nov 16, 2026, Cocrystal Pharma, Inc. (COCP) is the stronger overall head-to-head candidate over AIM ImmunoTech Inc. (AIM) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). COCP carries a Unified Composite Score of 47.1/100 (HOLD) at $1.00 (N/M Forward P/E, -3063.6% operating margin), whereas AIM carries 52.8/100 (HOLD) at $0.13 (2.0x Forward P/E, -11724.2% operating margin). Composite vs. Pillar Nuance: While AIM currently prints a higher short-term Unified Composite Score (52.8/100 HOLD vs. COCP 47.1/100 HOLD), COCP captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-3063.6% vs. -11724.2% operating margin) and revenue trajectory (+26.9% vs. +4.0% YoY). Technical & Structure Timing Caution: COCP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3); meanwhile AIM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

COCP leads the Growth & Scale pillar: COCP posts +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin), compared with AIM at +4.0% YoY revenue growth and +0.0% YoY earnings growth on $95,000 TTM revenue (-23.2% gross margin, -11724.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), COCP cumulative revenue shifted N/A while AIM shifted N/A. In operating R&D and SG&A reinvestment, COCP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AIM.

AIM screens cheaper on headline valuation multiples. COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 49.7x EV/Revenue (unreported FCF margin), whereas AIM trades at 2.0x Forward P/E, 2.0x Trailing P/E, 0.71x PEG, and 62.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCP (-311.7% ROE) versus AIM (-2382.3% ROE) capital efficiency.

In options market volatility and institutional positioning, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 54% Vol realized risk). By comparison, AIM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 69% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.